Navigation Links
Development of a therapeutic algorithm for optimal nosebleed management
Date:8/26/2013

Approximately 60 percent of people experience epistaxis, commonly known as nosebleed, at least once in their lifetime. Of those who experience nosebleed, six percent require medical treatment. A study in the September 2013 issue of OtolaryngologyHead and Neck Surgery, explores which nosebleed treatment options demonstrate the best outcomes.

"Although data exist on the efficacy of the different epistaxis management techniques, outcome comparisons between the modalities for both primary management as well as management of cases of recurrence are currently lacking," the authors stated.

The study analyzed various treatment outcomes of adult patients with epistaxis presenting to otolaryngologists at a tertiary care center between 2005 and 2011. The authors observed 147 patients (94 men and 53 women) who underwent cauterization, tamponade or nondissolvable packing, and/or proximal vascular control through embolization or surgical ligation. Treatment outcomes were then compared with the intent to derive an algorithm for optimal nosebleed management.

According to the study, nondissolvable packing demonstrated the highest rate of failure or recurrence (57.4 percent) for initial bleed management. Chemical cautery was significantly more successful in achieving lasting hemostasis for the first bleeding episode. The authors also found that the duration of the nondissolvable pack placement had no significant impact on nosebleed recurrence. Furthermore, among patients who failed initial management, those who next underwent more invasive procedures such as cautery, embolization or surgical ligation experienced better outcomes and shorter inpatient stays.

Because the subgroup analyses were limited in size for some of the treatment groups in this study, the authors urge caution when considering these findings.

Although most cases of nosebleed do not require medical intervention, those patients who do present to a tertiary care otolaryngologist and need medical attention require a systematic, stepwise approach to address their condition. This study demonstrates "good outcomes with initial treatment with chemical cautery and with procedures that achieve directed vascular control in patients who develop epistaxis recurrence."


'/>"/>

Contact: Lindsey Walter
newsroom@entnet.org
703-535-3762
American Academy of Otolaryngology - Head and Neck Surgery
Source:Eurekalert

Related medicine news :

1. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
2. Kudos for 3 NJIT Enterprise Development Center high-tech companies
3. 2 repressor genes identified as essential for placental development
4. Louisiana Tech University professor earns NSF Early Career Development grant
5. Advanced genetic screening method may speed vaccine development
6. New biospecimens management system in development
7. Developmental Woes Common in Siblings of Children With Autism
8. Mutations impair childhood growth and development by disrupting organization of chromosome pairs
9. Penn and Cornell researchers spearhead the development of new guidelines for veterinary CPR
10. Study sheds new light on role of genetic mutations in colon cancer development
11. The first day of development -- a window to successful pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving ... program, has teamed up with Citizens Opposed to Domestic Abuse in support of its ... support all those victimized by the fear of violence in their own homes, donations ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... enrichment program serving the greater Venice, FL area, has initiated a fundraiser for ... a car accident just four days after Christmas. To support this beautiful child ...
(Date:2/8/2016)... ... February 08, 2016 , ... T.E.N., ... that nominations will be accepted February 8, 2016 through May 8, 2016 ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... frequently. While a significant number of women and men with eating disorders report ... itself, that best predicts the development of an eating disorder. , At ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Discover the ... visit over 1,400 booths and 700 companies. Attendees also get to see the ... Colorado Garden & Home Show , at the Colorado Convention Center - 700 ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... -- Vestagen Technical Textiles, Inc., a medical technology company ... other demanding applications, today announced it has named ... Dale Pfost , PhD, who was serving as interim ... Vestagen,s Board of Directors. ® , the ... that combines fluid repellent, antimicrobial and breathability properties. VESTEX ...
(Date:2/8/2016)... Feb. 8, 2016  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... injectable drug delivery systems, today announced that it will release ... December 31, 2015 after market close on February 9, 2016. ... call to discuss these financial results.    About ... --> About Unilife Corporation ...
(Date:2/8/2016)...  Astellas Pharma Inc. President and Chief Executive Officer ... Robinson as president, Americas Operations, for Astellas US LLC, ... South America , effective April 1, 2016.  Robinson ... organization in the United States -- ... Yoshida , who is retiring in June 2016.  ...
Breaking Medicine Technology: